In April 2026, Heartflow, Inc., a California-based medical technology company specializing in AI-powered three-dimensional cardiac models, filed a comprehensive 180-page patent infringement complaint in the U.S. District Court for the Eastern District of Texas. The lawsuit alleges “one of the most egregious examples of piracy in the medical technology industry,” accusing Cleerly, Inc., a rival company founded by a former Heartflow consultant, of misappropriating Heartflow’s proprietary cardiovascular diagnostic technology, trade secrets, and confidential business information.
Heartflow’s complaint emphasizes the company’s substantial investment—amounting to hundreds of millions of dollars and decades of research protected by hundreds of patents—and the collaborative efforts of numerous scientists, engineers, and physicians that culminated in the world’s first AI-powered, non-invasive cardiac diagnostic platform. This platform has received recognition from the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS).
Cleerly responded on April 17, characterizing the lawsuit as an attempt to limit competition. The company stated, “We strongly disagree with the allegations and will vigorously defend against these baseless claims.” Cleerly’s official answer to the complaint is due by July 8, 2026.
The complaint traces Heartflow’s origins to 1978, recounting how a future co-founder, Dr. Charles Taylor, inspired by a personal medical experience, pursued medical research that eventually incorporated computer simulations of blood flow and medical image analysis by the 1990s. In 2010, Heartflow hired Dr. James K. Min, who signed a nondisclosure agreement and agreed to assign all rights to inventions and intellectual property developed during his tenure to Heartflow.
Heartflow alleges that without informing the company, Dr. Min founded Cleerly in 2016 while still bound by confidentiality, non-compete, and invention assignment obligations. The complaint asserts that Min used Heartflow’s confidential information to develop Cleerly’s competing products and simultaneously worked to undermine Heartflow’s business at his institution.
Additionally, Cleerly reportedly hired Heartflow’s former chief commercial officer, who had comprehensive access to Heartflow’s clinical, technical, and business operations and was also bound by confidentiality agreements.
Heartflow’s patented cardiac diagnostic platform is protected by over 600 patents, with six patents specifically asserted in the lawsuit. These patents relate to AI-powered cardiac imaging analysis and include:
- U.S. Patent No. 11,288,813: Systems and methods for anatomic structure segmentation in image analysis;
- U.S. Patent No. 11,382,569: Systems and methods for estimating blood flow characteristics from vessel geometry and physiology;
- U.S. Patent No. 9,770,303: Systems and methods for predicting coronary plaque vulnerability from patient-specific anatomic image data;
- U.S. Patent No. 9,839,399: Systems and methods for numerically evaluating vasculature;
- U.S. Patent No. 9,607,386: Systems and methods for correction of artificial deformation in anatomic modeling;
- U.S. Patent No. 11,013,425: Systems and methods for analyzing and processing digital images to estimate vessel characteristics.
The complaint describes these patents as covering “novel,” “groundbreaking,” “disruptive,” and “innovative” technologies that lacked predicate devices prior to Heartflow’s developments. It notes that these innovations have been recognized by the FDA, CMS, Cleerly’s own founder and CEO, and other industry stakeholders.
Heartflow further alleges that Cleerly has induced direct infringement of these patents by healthcare providers and hospitals through instructional materials such as videos, training sessions, webinars, and demonstrations.
The complaint highlights Heartflow’s pioneering AI-powered non-invasive cardiac diagnostic platform’s regulatory milestones, including FDA de novo clearance granted on November 26, 2014, and CMS’s assignment of a “New Technology” Ambulatory Payment Classification. Industry recognition and extensive citations in medical publications underscore Heartflow’s position as the most utilized AI-based cardiac technology in the United States. These factors support Heartflow’s arguments regarding patent eligibility and inventive concepts in AI and machine learning medical imaging claims, which are often critical in early patent litigation stages.
Heartflow Files Extensive Patent Infringement Suit Against Cleerly Over AI-Based Cardiac Technology Heartflow, Inc. has initiated a detailed patent infringement lawsuit in the U.S. District Court for the Eastern District of Texas against Cleerly, Inc., alleging unauthorized use of its AI-powered cardiac diagnostic pla... Read the full IIPLA article: https://iipla.org/news/heartflow-files-extensive-patent-infringement-suit-against-cleerly-over-ai-based-cardiac-technology